Healthcare, Pharma & Life Sciences

Simply Healthcare Foundation Gives $230K to Expand Pediatric Mental Health Program

Image
Simply Healthcare Foundation Gives $230K to Expand Pediatric Mental Health Program

Hollywood, Fla. – September 30, 2026 -- Joe DiMaggio Children's Hospital Foundation has secured a $230,000 grant from Simply Healthcare Foundation to expand New Solutions, a pediatric mental health treatment and suicide prevention program, over the next three years.

Grant funds care for 267 individuals over three years

The three-year grant began July 1 and will allow New Solutions to serve 267 individuals, targeting the gap between emergency psychiatric treatment and community-based behavioral health care. The program addresses children and adolescents who arrive at the emergency department in crisis but do not meet medical criteria for hospital admission or an involuntary examination under Florida's Baker Act.

CCAPP Merges Three Summits for 13th Annual California Addiction Conference

Image
CCAPP Merges Three Summits for 13th Annual California Addiction Conference

Los Angeles – September 30, 2026 -- The California Consortium of Addiction Programs and Professionals (CCAPP) will run its 13th Annual California Addiction Conference (CAC) from October 14-18, 2026, at the Sheraton Universal Hotel in Universal City, consolidating three previously separate summits into a single five-day program.

Vanda's HETLIOZ Hits Phase III Goal in Sleep Disorder Trial

Image
Vanda's HETLIOZ Hits Phase III Goal in Sleep Disorder Trial

Washington – September 30, 2026 -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) reported positive topline results from a pivotal Phase III study of HETLIOZ® (tasimelteon) 20 mg in adults with Delayed Sleep-Wake Phase Disorder (DSWPD), setting up a supplemental New Drug Application (sNDA) filing with the U.S. Food and Drug Administration (FDA).

Trial meets primary endpoint with statistically significant sleep-timing shift

The study, VP-VEC-162-3502 (NCT04652882), shifted sleep onset 42.5 minutes earlier in the HETLIOZ® arm (n=20) versus 5.4 minutes on placebo (n=20), a 37.1-minute difference (p=0.022). In an exploratory responder analysis, 60% of tasimelteon-treated participants (12/20) advanced sleep onset by at least 30 minutes, compared with 15% on placebo (3/20) (p=0.008).

Lilly's Retatrutide Cuts Weight 20.8%, A1C 1.6% in Phase 3 Trial

Image
Lilly's Retatrutide Cuts Weight 20.8%, A1C 1.6% in Phase 3 Trial

Indianapolis – September 30, 2026 -- Eli Lilly and Company (NYSE: LLY) reported that its investigational triple hormone receptor agonist retatrutide produced an average weight loss of 49.6 lbs (20.8%) over 80 weeks at the 12 mg dose in patients with type 2 diabetes and obesity, with more than half of participants no longer meeting BMI criteria for obesity. The Phase 3 TRIUMPH-2 results were presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes in Milan and simultaneously published in The Lancet.

Highest dose delivers weight loss up to 23.4% in heavier patients

Across the three tested doses, participants lost an average of 29.8 lbs (12.7%) at 4 mg, 45.4 lbs (19.1%) at 9 mg, and 49.6 lbs (20.8%) at 12 mg. Among patients with a baseline BMI of 35 or higher, the 12 mg dose produced an average loss of 60.8 lbs (23.4%), with 59.5% of all 12 mg participants no longer classified as having obesity by trial end.

Pressley Ridge Gathers 50+ Experts for W.Va. Kinship Care Summit

Bridgeport, W. Va. – September 30, 2026 -- Pressley Ridge convened more than 50 community partners, advocates, and child welfare experts at the Bridgeport Conference Center from September 15 to 18 for the B~Hope Conference and Summit, focused on advancing kinship care and family-centered support across West Virginia.

Conference spotlights two family-support frameworks

Sessions centered on the Family Centered Treatment Foundation® (FCT) model alongside the newly introduced Pressley Ridge B~Hope Embracing Kinship Caregivers curriculum, both aimed at equipping caregivers and families with practical resources to sustain kinship placements.

Home Helpers Franchisees Dow Named 2026 IFA Franchisee of the Year

Cincinnati – September 30, 2026 -- Beth and Phillip Dow, franchisees of Home Helpers Home Care in Newnan, Georgia, have been named 2026 Franchisee of the Year by the International Franchise Association, an honor they also received in 2015.

Newnan franchise projects $4.5 million in revenue for 2026

The Dows' operation, now in its 19th year, employs 150 caregivers and 14 operations staff serving 112 clients. The award was presented during the IFA26 Advocacy Summit in Washington, D.C., held Sept. 14-16, with a formal luncheon on Sept. 15.

Franchisees expand into Canton, Georgia market

Last month the Dows opened Home Helpers Home Care of Canton, Georgia, extending their footprint beyond the original Newnan territory ahead of their 20th anniversary with the brand next year.

Cytrellis Expands ellacor Skin-Tightening Device Into South Korea

Image
Cytrellis Expands ellacor Skin-Tightening Device Into South Korea

Woburn, Mass. – – September 30, 2026 -- Cytrellis Biosystems, Inc. has signed a commercialization agreement with KoreAx Co. Ltd. to launch its ellacor skin-removal device in South Korea, marking the company's second international market entry of 2026 after Australia.

South Korea's Ministry of Food and Drug Safety cleared ellacor in 2025

Ellacor is described as the first and only FDA-cleared, minimally invasive, in-office procedure that removes sagging skin without surgery or thermal energy. The device uses Micro-Coring technology and is approved for adults aged 22 and older with Fitzpatrick skin types I-IV.

Pathology Ventures Names Ex-Banker Stockey EVP for Sponsor Deals

Image
Pathology Ventures Names Ex-Banker Stockey EVP for Sponsor Deals

Shreveport, La. – September 30, 2026 -- Pathology Ventures, LLC (PVL), a physician-founded network representing more than 500 pathologists, has appointed Dominic Stockey as executive vice president to lead partnerships with pharmaceutical, diagnostic and research sponsors.

Former investment banker to run sponsor and enterprise development

Stockey joins PVL after seven years in investment banking, where he served as Vice President and worked on more than 15 closed transactions across diagnostics, life sciences and healthcare, including mergers and acquisitions and capital formation deals. At PVL, he will oversee business operations, sponsor and partner relationships, commercialization, contracting and program execution.

PhRMA Names Eric Cantor as Next President and CEO, Effective Nov. 9

Image
PhRMA Names Eric Cantor as Next President and CEO, Effective Nov. 9

Washington – September 29, 2026 -- The Pharmaceutical Research and Manufacturers of America (PhRMA) has named former House Majority Leader Eric Cantor as its next president and chief executive officer, effective November 9. Cantor succeeds Stephen J. Ubl, who has led the trade group since 2015 and will remain as a strategic advisor through January 15, 2027.

Dimora Medical Launches MegaSorb Foam Dressing for Elderly Wound Care

Image
Dimora Medical Launches MegaSorb Foam Dressing for Elderly Wound Care

New York – – September 29, 2026 -- Dimora Medical unveiled a silicone foam wound dressing built on its MegaSorbTM Dual-Action Absorption System, targeting moderate to heavy exudate wounds common among elderly patients with pressure ulcers and chronic wounds. The launch coincides with the 2026 United Nations International Day of Older Persons, observed under the theme "The Age of Longevity: Rethinking Systems for Longer Lives."

MegaSorb foam absorbs up to 15 times its own weight in wound exudate

The dressing uses a high-porosity polymer with an open-cell structure reaching up to 90%, enabling it to lock in exudate within one second and reduce leakage and backflow risk. Dimora Medical positions the technology as a direct response to gaps in traditional wound dressings, which frequently fail to manage moderate to heavy exudate, causing maceration of surrounding skin and painful dressing changes.